4524
MORISHITA JINTAN CO.,LTD.
森下仁丹
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
9,429
Mar 2022
9,563
Mar 2023
11,359
Mar 2024
12,406
Mar 2025
12,766
Operating profit(million JPY)
Mar 2021
223
Mar 2022
299
Mar 2023
569
Mar 2024
716
Mar 2025
804
Operating profit margin(%)
Mar 2021
2.37
Mar 2022
3.13
Mar 2023
5.01
Mar 2024
5.77
Mar 2025
6.3
Profit before tax(million JPY)
Mar 2021
252
Mar 2022
385
Mar 2023
623
Mar 2024
820
Mar 2025
772
Profit(million JPY)
Mar 2021
206
Mar 2022
283
Mar 2023
491
Mar 2024
697
Mar 2025
547
Total assets(million JPY)
Mar 2021
14,446
Mar 2022
14,479
Mar 2023
16,103
Mar 2024
17,183
Mar 2025
17,896
Cash and cash equivalents(million JPY)
Mar 2021
2,703
Mar 2022
2,138
Mar 2023
2,409
Mar 2024
1,092
Mar 2025
1,940
Cash flows from operating activities(million JPY)
Mar 2021
871
Mar 2022
543
Mar 2023
1,179
Mar 2024
196
Mar 2025
669
Cash flows from investing activities(million JPY)
Mar 2021
-502
Mar 2022
-463
Mar 2023
-474
Mar 2024
-1,152
Mar 2025
-701
Cash flows from financing activities(million JPY)
Mar 2021
-141
Mar 2022
-645
Mar 2023
-433
Mar 2024
-362
Mar 2025
880
Return on equity(%)
Mar 2021
2
Mar 2022
2.7
Mar 2023
4.5
Mar 2024
5.9
Mar 2025
4.5
Equity ratio(%)
Mar 2021
71.1
Mar 2022
72.2
Mar 2023
70.7
Mar 2024
70.7
Mar 2025
67.9
Earnings per share(JPY per share)
Mar 2021
50.69
Mar 2022
69.58
Mar 2023
120.55
Mar 2024
170.68
Mar 2025
133.78
Net assets per share(JPY per share)
Mar 2021
2,521.16
Mar 2022
2,563.38
Mar 2023
2,790.71
Mar 2024
2,972.34
Mar 2025
2,970.49
Dividend per share(JPY per share)
Mar 2021
37.5
Mar 2022
37.5
Mar 2023
40
Mar 2024
50
Mar 2025
55
Payout ratio(%)
Mar 2021
73.98
Mar 2022
53.89
Mar 2023
33.18
Mar 2024
29.29
Mar 2025
41.11
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.